Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Emphysema, Pulmonary Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

NCT01851642
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD, Cystic Fibrosis (CF)
Interventions
History and physical exam., Blood draw., Pulmonary function testing., Albuterol inhaler.
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2033
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Hypoxic Pulmonary Vasoconstriction Pilot Study

NCT03733470
View directory record Official record
Conditions
Emphysema
Interventions
Sildenafil study group
Drug
Lead sponsor
Eric A. Hoffman
Other
Eligibility
30 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jun 10, 2026, 5:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

NCT01776398
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 10, 2026, 5:05 PM EDT
Recruiting Phase 3 Interventional

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

NCT07555483
View directory record Official record
Conditions
Alpha 1 Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-PI
Drug · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 5:05 PM EDT
Recruiting No phase listed Observational

STRIVE Post-Market Registry Study

NCT04302272
View directory record Official record
Conditions
Emphysema
Interventions
Spiration Valve System (SVS)
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • Mountain View, California • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00424528
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions
Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
45 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Tucson, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease

NCT00992680
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
ROX Anastomotic Coupler System (ACS)
Device
Lead sponsor
ROX Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jun 10, 2026, 5:05 PM EDT
Completed No phase listed Observational

The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency

NCT03039335
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Not listed
Lead sponsor
Biocerna LLC
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fulton, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Jun 10, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

NCT00874497
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
tetomilast, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Torrance, California • Kissimmee, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

NCT00749411
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, GSK233705/GW642444
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Mobile, Alabama • Wheat Ridge, Colorado • Biddeford, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-668

NCT05727800
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
VX-668, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Tempe, Arizona • Gainesville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jun 10, 2026, 5:05 PM EDT
Not listed Phase 2 Interventional

Biological Effects of Quercetin in COPD Phase II

NCT06003270
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
Interventions
Quercetin 1000 mg, Quercetin 500 MG, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

NCT00630227
View directory record Official record
Conditions
Homogeneous Emphysema
Interventions
Biologic Lung Volume Reduction
Biological
Lead sponsor
Aeris Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Jun 10, 2026, 5:05 PM EDT
Terminated Not applicable Interventional

The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease

NCT00238082
View directory record Official record
Conditions
COPD
Interventions
HFA-134A Beclomethasone DIpropionate (QVAR)
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 10, 2026, 5:05 PM EDT
Completed No phase listed Observational Results available

Alpha-1 Carrier Genomics Study

NCT02810327
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, Emphysema, COPD, Smoking
Interventions
Genetic Sequencing
Genetic
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Jun 10, 2026, 5:05 PM EDT
Completed No phase listed Observational

Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center

NCT00870857
View directory record Official record
Conditions
HIV Infections, Emphysema, Chronic Obstructive Pulmonary Disease, Pneumocystis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jun 10, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Belcesiran in Patients With AATLD

NCT04764448
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Belcesiran, Placebo
Drug · Other
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Gainesville, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency

NCT03114020
View directory record Official record
Conditions
Emphysema, Alpha 1-Antitrypsin Deficiency
Interventions
Hyaluronic Acid Inhalation Solution, Placebo Inhalation Solution
Drug
Lead sponsor
Gerard Turino
Individual
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Miami, Florida • Fayetteville, New York • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jun 10, 2026, 5:05 PM EDT
Active, not recruiting Phase 2 Interventional

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions
SAR447537
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 10, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Jun 10, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional

COPD Resources, Education, and Activity Designed for You Study

NCT07125053
View directory record Official record
Conditions
COPD
Interventions
Education (self-guided), Education (counselor-led), Physical Activity, Inhaler Training
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 10, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals

NCT00001462
View directory record Official record
Conditions
Emphysema, Lung Diseases, Obstructive, Alpha 1-Antitrypsin Deficiency
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prostaglandin Inhibition for Emphysema

NCT02006576
View directory record Official record
Conditions
Emphysema
Interventions
600 mg ibuprofen three times daily for 48 weeks, Placebo three times daily
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
46 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Torrance, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jun 10, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations

NCT00774176
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
1,066 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
3
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Jun 10, 2026, 5:05 PM EDT